Seroatlas · Human Serome Atlas

LYNX1

Ly-6/neurotoxin-like protein 1

Also known as: LYNX1_HUMAN, SLURP2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P0DP58
Gene: LYNX1
Ensembl: ENSG00000180155
Chromosome: 8
Canonical length: 116 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a GPI-anchored, cell membrane bound member of the Ly6/uPAR (LU) superfamily of proteins containing the unique three-finger LU domain. This protein interacts with nicotinic acetylcholine receptors (nAChRs), and is thought to function as a modulator of nAChR activity to prevent excessive excitation. Alternatively spliced transcript variants have been found for this gene. Read-through transcription between this gene and the neighboring downstream gene (SLURP2) generates naturally-occurring transcripts (LYNX1-SLURP2) that encode a fusion protein comprised of sequence sharing identity with each individual gene product. [provided by RefSeq, Sep 2017]

Canonical amino-acid sequenceUniProt

116 residues, UniProt reviewed canonical sequence.

>P0DP58|LYNX1
     1  MTPLLTLILV VLMGLPLAQA LDCHVCAYNG DNCFNPMRCP AMVAYCMTTR TYYTPTRMKV
    61  SKSCVPRCFE TVYDGYSKHA STTSCCQYDL CNGTGLATPA TLALAPILLA TLWGLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYNX1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.43
Highest tissue expression: 125 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 125 nTPM
hippocampal formation: 97 nTPM
heart muscle: 74 nTPM
amygdala: 67 nTPM
hypothalamus: 55 nTPM
cerebellum: 52 nTPM

Single-cell type

other brain neurons: 27 nCPM
brain excitatory neurons: 26 nCPM
brain inhibitory neurons: 19 nCPM
choroid plexus epithelial cells: 16 nCPM
oligodendrocytes: 14 nCPM
astrocytes: 11 nCPM

Immune cell

non-classical monocyte: 18 nTPM
intermediate monocyte: 6.6 nTPM
myeloid DC: 1 nTPM
naive CD4 T-cell: 0.3 nTPM
total PBMC: 0.3 nTPM
classical monocyte: 0.2 nTPM

Brain region

cerebral cortex: 472 nTPM
hippocampal formation: 359 nTPM
white matter: 303 nTPM
pons: 290 nTPM
medulla oblongata: 262 nTPM
thalamus: 253 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.36
gnomAD pLI: 0.03
gnomAD missense Z: 0.97
DepMap mean gene effect: 0.18
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LYNX1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

KCNA2

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYNX1 as an antibody target. Whether an autoantibody or antibody against LYNX1 could matter depends on whether native LYNX1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYNX1 is annotated at the cell surface, where native LYNX1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LYNX1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...